Northwestern Memorial Hospital

Hologic to Unveil Groundbreaking AI Research at ECR 2024

Retrieved on: 
Tuesday, February 27, 2024
Other Health, Software, Research, Radiology, Oncology, Medical Devices, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Health, Breast cancer, Algorithm, Artificial intelligence, AI, Education, HOLX, CEM, European, Cancer, Genius, Northwestern Memorial Hospital, Business, CAD, Medical imaging, ECR, Sittard-Geleen, Mammography, Bayer, Associate, Congress, Machine learning, Breast imaging, Workflow

The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists.

Key Points: 
  • The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists.
  • “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum.
  • “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography.
  • Hologic’s Genius AI® Detection technology is a cutting-edge solution now commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024.

FDA Clearance of VerTouch™ from IntuiTap Medical Could Revolutionize Epidurals

Retrieved on: 
Thursday, February 8, 2024
FDA, Medical Devices, Women, Consumer, Health, Hand, MD, Texas Medical Center, Anxiety, Medical education, Safety, Society, Northwestern Memorial Hospital, Multimedia, Hospital, Patient, Radiology, Entrepreneurship

IntuiTap Medical proudly announces FDA clearance of their cutting-edge medical device, VerTouch.

Key Points: 
  • IntuiTap Medical proudly announces FDA clearance of their cutting-edge medical device, VerTouch.
  • This milestone achievement for IntuiTap signifies a significant leap forward in the company’s mission to set a new standard of care for the millions of Americans who undergo these procedures annually.
  • View the full release here: https://www.businesswire.com/news/home/20240208434976/en/
    FDA clearance validates the safety and effectiveness of IntuiTap’s novel device, VerTouch, which has undergone rigorous testing at medical institutions across the United States including Northwestern Memorial Hospital and the Texas Medical Center.
  • Unsurprisingly, this method can be both unpredictable and unreliable which results in first-attempt failures in 40-60% of cases.

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024
Partnership, Northwestern University, Certification, AAPS, ABMS, Plastic surgery, Knowledge, Science, Bachelor, Feinberg School of Medicine, Rhinoplasty, Division, Medical specialty, Internet celebrity, Expert, Plastic and Reconstructive Surgery, Biomedicine, Mentorship, Literature, MD Anderson Cancer Center, Elective surgery, Honors colleges and programs, Medical education, Harvard University, Harvard Medical School, Physician, Northwestern Memorial Hospital, Breast surgery, Biomedical engineering, Cure, Pearl, Editorial, Associate, University, Student, Editor-in-chief, Dentistry

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

Retrieved on: 
Tuesday, January 2, 2024
Hospital, FDA, Northwestern Memorial Hospital, Food and Drug Administration, LOI, Device, OXY, Newsweek, Nursing

RA'ANANA, Israel, Jan. 2, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois ("Northwestern").

Key Points: 
  • RA'ANANA, Israel, Jan. 2, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois ("Northwestern").
  • Northwestern, ranked as the eighth best hospital in the United States by Newsweek in 2023, is part of Northwestern Medicine, which operates several hospitals in the United States.
  • The LOI expresses the mutual interest by both parties to further explore potential collaboration regarding the evaluation of how the INSPIRA ART100 device ("Device" or "Devices") aligns with Northwestern's needs in clinical scenarios, workflow efficiency, and healthcare delivery.
  • Northwestern will also agree to purchase all necessary disposables to operate the Devices and will, in turn, provide Inspira Technologies with valuable data and Device diagnostics from its usage.

Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals

Retrieved on: 
Thursday, December 14, 2023
Recycling, Medical Supplies, Health, Medical Devices, Environment, Hospitals, Other Health, Syringe, NYSE, PVC, Carbon footprint, Baxter International, Nursing, Needle, Patient, Multimedia, Northwestern Memorial Hospital, Polyvinyl chloride, Baxter, Hospital, Northwestern Medicine

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot.
  • View the full release here: https://www.businesswire.com/news/home/20231214638041/en/
    Photo of IV bag recycling provided by Northwestern Medicine.
  • All IV bags involved in this pilot were made of PVC, one of the most widely used plastic materials in medical products.
  • In recent years, Baxter has introduced several programs to facilitate recycling for patients and hospitals in Australia, New Zealand, Guatemala and Colombia.

ReValve Solutions Announces Successful First-in-Human with Next Generation TMVR Technology

Retrieved on: 
Wednesday, November 29, 2023
Health, Medical Devices, Surgery, Health Technology, Clinical Trials, Cardiology, Biotechnology, LVOT, East Carolina University, Medical director, Chair, TMVR, Mitral regurgitation, History, Patient, Heart, Northwestern Memorial Hospital, Male, Interventional cardiology, Heart failure, Tricuspid valve, Mitral valve, Retail Solutions Inc., University, Patent, Medical device

ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System.

Key Points: 
  • ReValve Solutions Inc. (ReValve), which has developed a next generation technology for Transcatheter Mitral Valve Replacement (TMVR), announced that an 81-year-old male, with a history of heart failure, a series of failed surgical by-pass grafts and severe mitral regurgitation (MR 4+), was successfully treated with the Palmetto System.
  • ReValve’s technology is designed to replace the Mitral Valve while also preserving the heart’s natural basal left ventricular function.
  • Our flexibility and four-point securement system provide a patent LVOT and maintains left ventricular function throughout recovery,” said Julie Logan Sands, Founder and CEO ReValve Solutions.
  • ReValve’s first-of-its-kind TMVR is thoughtfully designed to expand the treatable population of patients suffering from Mitral Valve Disease,” added Sands.

Xentria’s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrolled in Study

Retrieved on: 
Wednesday, November 15, 2023
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Principal, Food, European Medicines Agency, Sarcoidosis, Disease, EMA, Patient, Northwestern Memorial Hospital, FDA, Therapy, Diagnosis, Partnership, Orphan drug, Orphan, Drug development, Pharmaceutical industry

Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, today announced that its lead candidate, XTMAB-16, has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

Key Points: 
  • Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet clinical needs, today announced that its lead candidate, XTMAB-16, has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
  • The company is also announcing that the first US patient has been enrolled in its global study to evaluate XTMAB-16 as treatment for the rare disease sarcoidosis.
  • The medicine must fulfill certain criteria to receive designation as an orphan medicine, including the potential to bring health benefits compared to existing treatments.
  • XTMAB-16 previously received Orphan Drug Designation in the US from the Food and Drug Administration (FDA) in November 2020.

Fasano Longevity Conference Covers Politics, Investments, and Medical Research

Retrieved on: 
Thursday, November 9, 2023
Consulting, Other Professional Services, Professional Services, Insurance, Research, Life expectancy, Northwestern Memorial Hospital, Ultrasound, Blood–brain barrier, Next, Conference, Longevity, Senescence, Use

Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.

Key Points: 
  • Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.
  • The conference, which was in hybrid format, with about 170 attending in person and 30 attending virtually, focused on a wide range of topics bearing on longevity markets, medical research, and the primary elections.
  • It covered a very interesting mix of topics bearing on longevity markets and some very cutting-edge research.” Fasano described the Conference as investor focused.
  • Next year’s Fasano Longevity Conference will be held on Monday, November 4th in Washington, DC.

Hubly Drill Used in Life-Saving Bedside Procedures

Retrieved on: 
Thursday, November 2, 2023
Radiology, Neurology, Ventriculostomy, Northwestern Memorial Hospital, SMART, Safety, Patient, Printed circuit board, Neurosurgery, Northwestern University, Greater Houston, Northwestern Medicine

Dr. Matthew Potts, Associate Professor of Neurosurgery, Neurology, and Radiology at Northwestern Medicine, performed the very first successful procedure with Hubly Drill.

Key Points: 
  • Dr. Matthew Potts, Associate Professor of Neurosurgery, Neurology, and Radiology at Northwestern Medicine, performed the very first successful procedure with Hubly Drill.
  • "This drill is faster and easier to use than the standard hand-powered drills currently used for emergent bedside procedures," said Dr. Potts, after drilling the hole in 16 seconds—far faster than the average for a hand-crank drill.
  • Dr. Sabih Effendi, neurosurgeon and Stroke Medical Director in the Greater Houston area, used Hubly Drill mere hours later.
  • Hubly is the first bedside-ICU neurosurgical drill suitable for this millennium."

Fasano Longevity Conference to Cover Politics, Investments and Medical Research

Retrieved on: 
Tuesday, October 24, 2023
Insurance, Finance, General Health, Health, Consulting, Professional Services, Health Insurance, Other Health, Local Investing Opportunity Network, Life expectancy, Longevity, MAAA, Fasano, Science, Originality, Uncertainty, Conference, Hart, Northwestern Memorial Hospital, Research, Ultrasound, Brain, Obesity, Actuarial science, Politics, Blood–brain barrier, ASA, Mortality, Harte Research Institute for Gulf of Mexico Studies, LARA, Risk management, Life insurance, Ageing

The Fasano Longevity Conference , which will be held on November 6th in Washington, DC, will explore a broad range of subjects and feature industry experts to discuss relevant topics bearing on longevity markets.

Key Points: 
  • The Fasano Longevity Conference , which will be held on November 6th in Washington, DC, will explore a broad range of subjects and feature industry experts to discuss relevant topics bearing on longevity markets.
  • Will Ketterer , Obra Capital, Longevity CIO: The Impact of Interest Rates on Structured Settlements and Other Longevity Sensitive Assets.
  • Rahul Nawander , Fasano Associates Medical Director: An analysis on the Relationship Between Obesity and Increased Mortality
    Said Michael Fasano, "This year's conference has something for everyone - from politics to breakthrough medical research."
  • With a registration fee of only $595 and eight original presentations, Fasano characterized his conference as "the best value in the business."